CD8A and neoplasm: In detail, CD8+ TILs have been shown to directly kill tumor cells when presented with neoantigens and are also capable of activating apoptosis-inducing FAS–FASL pathways; CD4+ T cells play a regulatory role by differentiating into different phenotypes, such as Th1, Th2, Th17 and Treg [67,68].